Advanced Search

Technical Analysis for VIE - Viela Bio, Inc.

Grade Last Price % Change Price Change
grade C 26.7 -0.60% -0.16
VIE closed down 0.6 percent on Friday, December 13, 2019, on 1.61 times normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Down
See historical VIE trend table...
Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish -0.60%
Multiple of Ten Bearish Other -0.60%
Upper Bollinger Band Touch Strength -0.60%
20 DMA Support Bullish -5.25%
Pocket Pivot Bullish Swing Setup -5.25%
Doji - Bearish? Reversal -5.25%
Crossed Above 20 DMA Bullish -4.61%
Outside Day Range Expansion -4.61%
Older signals for VIE ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
VIE Chart by TradingView
Basic chart:

Profile

Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. Its lead product candidate, inebilizumab, is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.
Medicine Biotechnology Medical Specialties Monoclonal Antibodies Autoimmune And Inflammatory Diseases Humanized Antibody Monoclonal Antibody Therapy Tolerx

Is VIE a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 0 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Dec 11 Viela Bio initiates mid-stage VIB4920 study
Dec 11 Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
Nov 14 VIELA BIO EPS misses by $64.33
Nov 14 Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
Nov 12 3 “Strong Buy” Biotech Stocks That Recently Went Public
Oct 28 Sell-siders like Viela Bio in premarket action
Oct 11 Gates-Backed Vir Biotechnology Flops in Trading Debut
Oct 9 The Daily Biotech Pulse: FDA Approves Clinuvel Drug, Aclaris Files Patent Lawsuit Against Taro, Viela Out-Licenses Autoimmune Disorder Drug
Oct 9 Viela Bio inks deal with Mitsubishi Tanabe Pharma to develop inebilizumab in Asia
Oct 9 Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
See more VIE news...

Indicators

Indicator Value
52 Week High 33.7
52 Week Low 18.2
Average Volume 129,463
200-Day Moving Average 0.00
50-Day Moving Average 24.70
20-Day Moving Average 27.39
10-Day Moving Average 27.00
Average True Range 3.10
ADX 12.91
+DI 20.07
-DI 14.24
Chandelier Exit (Long, 3 ATRs ) 23.30
Chandelier Exit (Short, 3 ATRs ) 33.39
Upper Bollinger Band 30.89
Lower Bollinger Band 23.88
Percent B (%b) 0.4
BandWidth 25.60
MACD Line 0.54
MACD Signal Line 0.89
MACD Histogram -0.3545
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 32.19
Resistance 3 (R3) 32.60 31.19 31.28
Resistance 2 (R2) 31.19 29.79 30.98 30.97
Resistance 1 (R1) 28.94 28.92 30.07 28.53 30.66
Pivot Point 27.53 27.53 28.09 27.32 27.53
Support 1 (S1) 25.28 26.13 26.41 24.87 22.74
Support 2 (S2) 23.87 25.26 23.66 22.43
Support 3 (S3) 21.62 23.87 22.13
Support 4 (S4) 21.21